{
    "nct_id": "NCT05935748",
    "official_title": "A Phase 2 Trial to Evaluate the Safety and Efficacy of NKT2152 in Combination with Palbociclib (Doublet) and with Palbociclib and Sasanlimab (Triplet) in Subjects with Advanced or Metastatic Clear Cell Renal Cell Carcinoma",
    "inclusion_criteria": "* Must have locally advanced or metastatic ccRCC and have progressed or relapsed after at least 1 prior anti-VEGF/VEGFR systemic therapy and 1 ICI.\n* Measurable disease per the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)\n* KPS score of at least 70%\n* Able to swallow oral medications.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active CNS metastases and/or carcinomatous meningitis\n* Has had any major cardiovascular event within 6 months or clinically significant cardiovascular disease\n* Major surgery (eg, GI surgery, removal or biopsy of brain metastasis) within 3 months before administration of study drug.\n* Has known HIV\n* History of hepatitis B or known active hepatitis C infection\n* Has received prior treatment with NKT2152, other HIF2Î± inhibitors, other CDK 4/6 inhibitors, palbociclib, or sasanlimab\n* Radiation therapy for bone metastasis within 2 weeks, or any other external radiation therapy within 4 weeks before administration of the first dose of study treatment\n* Corrected QT interval calculated by Fridericia formula (QTcF) > 480 ms within 28 days prior to first dose\n* Hypoxia or requires intermittent or chronic supplemental oxygen or any chronic lung condition which has required supplemental oxygen in the past\n* Has a history of interstitial lung disease\n* Has any active or recent history of a known or suspected autoimmune disease",
    "miscellaneous_criteria": ""
}